World Health Organization site
Skip Navigation Links

Main
Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: REBEC
Last refreshed on: 29 April 2013
Main ID:  RBR-63xvgf
Date of registration: 10/05/2012
Primary sponsor: Universidade Estadual do Oeste do Paraná - UNIOESTE - Cascavel, PR, Brazil
Public title: Analysis of low level laser therapy in the treatment of patients with fibromyalgia
Scientific title: Analysis of low level laser therapy in the treatment of patients with fibromyalgia
Date of first enrolment: 10/01/2011
Target sample size: 20
Recruitment status: data analysis completed
URL:  http://www.ensaiosclinicos.gov.br/rg/RBR-63xvgf/
Study type: 
Study design:  Therapeutic, parallel, 2-arms, single-blinded, randomized clinical trial.  
Countries of recruitment
Brazil
Contacts
Name: João   Ruaro
Address:  Rua Trairi, s/n 59200-000 Santa Cruz/RN Brazil
Telephone: (84)3291-2411
Email: joaoruaro@bol.com.br
Affiliation:  Universidade Federal do Rio Grande do Norte
Name: João   Ruaro
Address:  Rua Trairi, s/n 59200-000 Santa Cruz/RN Brazil
Telephone: (84)3291-2411
Email: joaoruaro@bol.com.br
Affiliation:  Universidade Federal do Rio Grande do Norte
Key inclusion & exclusion criteria
Inclusion criteria: Clinical diagnosis of fibromyalgia;
Age between 20 and 80 years;
Signing the consent form;

Exclusion criteria: Don´t have

Age minimum: 20Y
Age maximum: 80Y
Gender: -
Health Condition(s) or Problem(s) studied
Fibromyalgia and Quality of life
C05.651.324
I01.800
C10.597.617
Intervention(s)
Twenty patients divided into treatment group (TG, n=10) and placebo group (PG, n=10). The TG was submitted to low level laser GaAlAs (Gallium Arsenide and Aluminum) 670 nm, 4 J/cm2 in the 18 predetermined anatomical sites, called tender points, 3 times a week for 4 weeks. The evaluation was made by specific form, Fibromyalgia Impact Questionnaire (FIQ), Medical Outcome Survey Short-Form 36 (SF-36), McGill Pain Questionnaire and Visual Analogue Scale (VAS) of pain.
Primary Outcome(s)
Possible improvement in the symptom of pain in patients with fibromyalgia, as measured by the McGill Pain Questionnaire and the visual analog scale. The McGill Pain Questionnaire consists of 78 words used to describe pain, qualitatively similar, grouped into four categories: sensory-discrimativo, sensory, affective, cognitive and miscellaneous. It is expected to reduce the contents of this questionnaire. The visual analog scale of pain consists of a line of 10 cm, where 0 represents no pain and 10 representing the worst pain imaginable, and is recommended for adults. It is expected that the reduction in the scale. Moreover, it is expected to reduce the number of tender points, measured between the initial and final assessment.
Secondary Outcome(s)
Increase the quality of life as measured by the SF-36 and FIQ. The SF-36 includes eight scales: physical functioning, role limitations due to physical health, bodily pain, general health perceptions, vitality, social functioning, role limitations due to emotional problems, and mental health. Shows a final score of 0-100, where "0" is the worst overall health status and "100" the best general health. It is expected an increase in the score of the questionnaire. The FIQ evaluates 10 domains: physical functioning, wellness, work absenteeism, difficulties at work, pain, fatigue, stiffness, sleep disturbances, anxiety and depression. There are 11 items ranked by the Likert scale, which involves values from 0 (always) to 3 (never). It is expected to decrease the score of the questionnaire.
Secondary ID(s)
Protocolo 015915/2005
Source(s) of Monetary Support
Universidade Estadual do Oeste do Paraná - UNIOESTE - Cascavel, PR, Brazil
Secondary Sponsor(s)
Universidade do Vale do Paraíba - UNIVAP - São José dos Campos, SP, Brazil
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.1 - Version history